BioCentury
ARTICLE | Company News

Intracel, OxiGene deal

April 30, 2007 7:00 AM UTC

Intracel granted OXGN worldwide rights to a human MAb targeting B cells. OXGN plans to submit an IND for the MAb to treat an undisclosed indication by the end of 2009. Further terms were not disclosed...